In a filing, Procept BioRobotics Corp revealed its Officer Zadno Reza acquired Company’s shares for reported $0.98 million on Mar 06 ’25. In the deal valued at $61.31 per share,15,916 shares were bought.
Then, Waters Kevin bought 3,662 shares, generating $224,500 in total proceeds.
Before that, Shiblaq Hisham bought 3,588 shares. Procept BioRobotics Corp shares valued at $219,963 were divested by the Officer at a price of $61.31 per share.
Morgan Stanley initiated its Procept BioRobotics Corp [PRCT] rating to an Overweight in a research note published on December 02, 2024; the price target was $105. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid November with a ‘”a Hold”‘ rating. Piper Sandler began covering PRCT with “an Overweight” recommendation on August 11, 2023. William Blair started covering the stock on May 31, 2023. It rated PRCT as “an Outperform”.
Price Performance Review of PRCT
On Friday, Procept BioRobotics Corp [NASDAQ:PRCT] saw its stock fall -2.06% to $59.33. Over the last five days, the stock has lost -7.79%. Procept BioRobotics Corp shares have fallen nearly -26.32% since the year began. Nevertheless, the stocks have risen 27.92% over the past one year. While a 52-week high of $103.81 was reached on 01/06/25, a 52-week low of $45.56 was recorded on 03/04/25. SMA at 50 days reached $72.89, while 200 days put it at $74.85.
Levels Of Support And Resistance For PRCT Stock
The 24-hour chart illustrates a support level at 58.07, which if violated will result in even more drops to 56.82. On the upside, there is a resistance level at 60.80. A further resistance level may holdings at 62.28. The Relative Strength Index (RSI) on the 14-day chart is 36.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.11%. Stochastics %K at 27.13% indicates the stock is a holding.
The most recent change occurred on October 31, 2022 when BTIG Research began covering the stock and recommended ‘”a Neutral”‘ rating .
